J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes
Executive Summary
Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit
You may also be interested in...
J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005
Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13
J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005
Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13
J&J Oncology/HIV Marketing Company Will Be Tibotec In U.S.
J&J will use the Tibotec corporate identity for its newest pharmaceutical marketing division in the U.S